Who
Frank Verwiel
Director
Company insider
Files Form 4 as: Director, Intellia Therapeutics; Director, Achillion Pharmaceuticals; Director, AveXis; Director, Intermune.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $38K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 6 Apr 2012
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —11,450 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $38K1,505 at $25.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —11,515 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —7,737 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —6,473 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —4,425 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —7,688 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —5,197 at $0.00 | filing |
| 23 Jun 2021filed 25 Jun 2021 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —2,094 at $0.00 | filing |
| 23 Jun 2021filed 25 Jun 2021 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —3,382 at $0.00 | filing |
| 18 Jun 2020filed 19 Jun 2020 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —42,000 | filing |
News
Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
0 headlines in the last 90 days name Frank Verwiel; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.